Market Research Reports Global Ovarian Cancer Drugs Market 2019 | Page 2

several leading drugs could also potentially impact this market by encouraging the entry of new players.
These changing dynamics will impact the ovarian cancer market during the forecast period.
According to Market study, Rising incidence of ovarian cancer, owing to growing geriatric population
and unhealthy lifestyles, is one of the key trends escalating Ovarian Cancer Drugs Market growth.
Besides this, increasing adoption of novel drugs and presence of strong developmental pipeline are
estimated positively reinforce ovarian cancer treatment market.
Merck KGaA, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and
Pfizer Inc. today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100
study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by
maintenance therapy of avelumab in combination with talazoparib,* a poly (ADP-ribose) polymerase
(PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or
metastatic ovarian cancer (Stage III or Stage IV). The alliance has notified health authorities and trial
investigators of the decision to discontinue the trial.
AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today
announced positive results from the Phase 3 POLO trial. Results from the trial showed a statistically-
significant and clinically-meaningful improvement in progression-free survival (PFS) with LYNPARZA
versus placebo. The safety and tolerability profile of LYNPARZAwas consistent with previous trials.
Ovarian Cancer Drugs Market Covers the Table of Contents With Segments, Key Players And Region.
Based on Product Type, Ovarian Cancer Drugs Market is sub segmented into Alkylating Agents, Mitotic
Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors. On the Basis of Application, Market is
sub segmented into Hospital Pharmacies, Drug Stores, Online Pharmacies.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/162795 .
Major Players profiled in the Ovarian Cancer Drugs Market report incorporate: Allergan plc, Pfizer, Inc,
Merck KGaA, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson, Syndax Pharmaceuticals,
Clovis Oncology
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Ovarian Cancer Drugs in these regions, from 2014 to 2023 (forecast),
covering: North America, Europe, Asia Pacific, Middle East & Africa and South America.
The report is a compilation of first-hand information, qualitative and quantitative assessment by
industry analysts, inputs from industry experts and industry participants across the value chain. The
report provides in-depth analysis of parent market trends, macro-economic indicators and governing
factors along with market attractiveness as per segments. The report also maps the qualitative impact of
various market factors on market segments and geographies.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation